PHARMEXCIL Boosts Govt Engagement to Drive India's $30B Pharma Export Growth

• PHARMEXCIL engaged with Commerce, Pharma, and DGFT departments to strategize India's generic drug export growth.
• India's pharma exports reached $30.47 billion in FY25, showing 9.4% year-on-year growth despite global pricing pressures.
• Key discussions focused on policy alignment, trade facilitation, innovation, and strengthening MSME participation in exports.
• Initiatives like Chintan Shivir for MSMEs and iPHEX 2026 aim to broaden exporter base and showcase India's capabilities.
• A growing domestic market, projected to reach $130 billion by 2030, provides a strong base for export-led growth.

Why It Matters: PHARMEXCIL intensifies government collaboration to propel India's pharma exports beyond $30 billion, focusing on MSMEs and innovation.